Headline Details

Spark's price for Luxturna blindness gene therapy too high: ICER

Published on: Fri, 12 Jan 2018 20:33:57 UTC
News Agency: Reuters
Description:
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Click here for FULL Story on Reuters

Also happening now

HeadlineNews Agency
U.S. opposed to Koreas' plan for no-fly zone over border: sources Reuters
French finance minister Le Maire cancels trip to Saudi conference Reuters
Freed Vietnamese dissident 'Mother Mushroom' arrives in U.S.: sources Reuters
Turkish investigators search Saudi consulate premises again Reuters
Singapore charges two over North Korea luxury goods sanctions: paper Reuters